Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 23, 2026
TickeronGET DAILY SIGNALS
Why Is Evommune (EVMN) Stock Down 4.03% Today?

Why Is Evommune (EVMN) Stock Down 4.03% Today?

Key Takeaways

  • EVMN shares were down roughly 4.03% in Thursday's session, extending a prolonged slide toward their 52-week low.
  • The primary driver is persistent negative sentiment following consecutive clinical setbacks, including the Phase 2b miss of lead candidate EVO756 in chronic spontaneous urticaria.
  • Secondary pressures include a wave of analyst price-target cuts, UBS's recent Neutral initiation with an $8 target, and heavy institutional selling.
  • The decline diverges from a broadly firm healthcare sector, underscoring company-specific weakness rather than macro pressure.
  • Traders are watching for further pipeline updates on EVO301 and the next quarterly report for signs of stabilization.
  • For deeper insight, explore Price Targets, Earnings, and Forecast data for EVMN.
  • To discover AI-driven trading strategies, visit Tickeron's Trending AI Robots.

Opening Summary

Evommune, Inc. (EVMN), a clinical-stage biotechnology company based in Palo Alto, California, develops therapies targeting the drivers of chronic inflammatory diseases such as atopic dermatitis, chronic spontaneous urticaria, and ulcerative colitis. The stock fell about 4.03% on Thursday, trading near $5.00 versus a prior close of $5.21, as selling pressure continued to push shares toward their 52-week low of $5.09. The move extends a multi-week downtrend driven by investor unease over the company's clinical pipeline following a string of trial disappointments.

Pipeline Setbacks Continue to Weigh on Sentiment

The dominant catalyst behind EVMN's decline is the lingering fallout from clinical failures. In late June, the company announced that its lead oral candidate, EVO756, missed the primary endpoint in a Phase 2b trial for moderate-to-severe chronic spontaneous urticaria, erasing roughly 38% of shareholder value in a single session and prompting the company to halt development of the drug for that indication. A subsequent Phase 2 readout for another MRGPRX2 antagonist program also failed in September, compounding doubts about the platform's broader potential. Although the company has pivoted its narrative to EVO301, its IL-18 binding protein candidate, the repeated setbacks have left investors in a cautious, risk-averse posture.

Analyst Cuts and Institutional Selling Add Pressure

Wall Street has steadily lowered its expectations in response. Multiple firms have reduced price targets, with UBS initiating coverage in October at a Neutral rating and an $8 target, and firms such as Leerink Partners and RBC trimming their objectives. The downgrade cycle has reinforced the bearish tone. On the institutional side, disclosures showed that early backer Andera Partners reduced its stake by roughly 93% during the third quarter, a move that compounded concerns about conviction among long-term holders even as some new funds established positions.

Market Context and Trading Activity

The slide in EVMN stands out because it has diverged from a relatively firm healthcare backdrop. While the broader healthcare sector has posted gains in recent weeks, EVMN has recorded multiple consecutive weekly declines and now trades well below both its 50-day and 200-day moving averages. Shares sit just pennies above the $5.09 52-week low, a technically vulnerable level, and remain far beneath the $33.20 52-week high. The stock's heavy short interest and elevated volatility have added to the choppy, downward-biased trading pattern.

What Comes Next for EVMN

Looking ahead, the focus shifts to whether EVMN can rebuild credibility with investors. The company has highlighted positive Phase 2a data for EVO301 in atopic dermatitis and plans to advance the program, with a subcutaneous Phase 2b dose-ranging trial expected to begin in mid-2027. Near term, the next quarterly earnings report will be closely watched for updates on cash runway, trial timelines, and spending. The company's balance sheet, with a sizeable cash position, provides some cushion, but execution risk remains elevated given the recent trial misses. Further analyst revisions and any new pipeline data are likely to set the tone for the stock in the weeks ahead.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing AI trading bots. Tickeron offers hundreds of AI-driven bots covering thousands of tickers, but only those demonstrating the most robust performance under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to explore. Visit Trending AI Robots to discover the strategies currently leading the rankings.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: EVMN

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for EVMN turns positive, indicating new upward trend

EVMN saw its Momentum Indicator move above the 0 level on October 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator turned positive. In 16 of the 17 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for EVMN just turned positive on October 19, 2026. Looking at past instances where EVMN's MACD turned positive, the stock continued to rise in 4 of 6 cases over the following month. The odds of a continued upward trend are 67%.

The 10-day moving average for EVMN crossed bullishly above the 50-day moving average on November 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

Following a +12.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVMN advanced for three days, in 33 of 41 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The 10-day RSI Indicator for EVMN moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 2 similar instances where the indicator moved out of overbought territory. In 2 of the 2 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 11 of 11 cases where EVMN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

EVMN moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

EVMN broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for EVMN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.869) is normal, around the industry mean (3.592). P/E Ratio (-0.562) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (34.014) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. EVMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
1841 Page Mill Road
Phone
+1 925 247-4481
Employees
48
Web
https://www.evommune.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.